The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBlackstone Loan Regulatory News (BGLF)

Share Price Information for Blackstone Loan (BGLF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.59
Bid: 0.57
Ask: 0.61
Change: 0.00 (0.00%)
Spread: 0.04 (7.018%)
Open: 0.59
High: 0.59
Low: 0.59
Prev. Close: 0.59
BGLF Live PriceLast checked at -
Blackstone/GSO Loan Financing is an Investment Trust

To provide shareholders with stable and growing income returns, and to grow the capital value of the investment portfolio by exposure to all debt tranches of CLOs (CLO Income Notes and other CLO Securities) and in Loan Warehouses.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of C Shares postponed

3 Jan 2019 17:16

RNS Number : 1698M
Blackstone / GSO Loan Financing Ltd
03 January 2019
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT OR ANY COPY OF IT.

This announcement is not an offer of securities for sale or subscription in the United States of America, Canada, Japan, Australia, South Africa or any other jurisdiction. This announcement is an advertisement and not a prospectus. Investors should not purchase or subscribe for any transferable securities referred to in this announcement except on the basis of information contained in the prospectus dated 23 November 2018 (the "Prospectus") published by Blackstone / GSO Loan Financing Limited.

 

3 January 2019

Blackstone / GSO Loan Financing Limited

("BGLF" or the "Company")

Issue of C Shares postponed

The Rollover Offer announced on 23 November 2018, whereby shareholders in Carador Income Fund plc ("Carador") were provided with the opportunity to elect to rollover their investment in Carador into an investment in newly issued C Shares of the Company, closed at 9.00 a.m. on 21 December 2018.

As announced on 21 December 2018, the issuance of C Shares to Carador shareholders electing to participate in the Rollover Offer is subject to the satisfactory completion of the requisite AML checks. In the event the Company is unable to satisfactorily complete these AML checks in respect of any Carador shareholder, such Carador shareholder's election to participate in the Rollover Offer will be rejected by the Company.

It was expected that these AML checks would be completed and new C Shares would be allotted and admitted to trading on 4 January 2019. However, partly due to seasonal factors, they are taking slightly longer than expected to complete and admission is now expected to occur on Monday 7 January 2019.

A further announcement and details of any other changes to the expected timetable for Admission will be notified by the Company through a Regulatory Information Service.

Further information

Further information is set out in the Prospectus and Circular published by the Company on 23 November 2018 which is available on the Company's website (www.blackstone.com/bglf) and from the Company's registered office at IFC 1, The Esplanade, St Helier, Jersey JE1 4BP. Unless otherwise indicated, capitalised terms used in this announcement shall have the meaning given to them in the Prospectus.

 

Enquiries:

John Armstrong-Denby / Nick Donovan

Fidante Capital, Joint Financial Adviser and Broker Tel: 020 7832 0900

 

James Maxwell / David Floyd

N+1 Singer, Joint Financial Adviser and Broker Tel: 020 7496 3000

 

BNP Paribas Securities Services S.C.A., Jersey Branch

IFC 1, The Esplanade, St Helier, Jersey, JE1 4BP

Company Secretary Tel: +44 (0) 1534 709181/813873

 

IMPORTANT INFORMATION

Any reference herein to future returns, distributions or realisations is a target and not a forecast and there can be no guarantee or assurance that it will be achieved.

The shares issued and to be issued by the Company (the "Shares") have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States. The Shares may not be offered, sold, resold, pledged, delivered, distributed or otherwise transferred, directly or indirectly, into or within the United States, or to, or for the account or benefit of, US persons (as defined in Regulation S under the Securities Act). No public offering of the Shares is being made in the United States.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act") and, as such, holders of the Shares will not be entitled to the benefits of the Investment Company Act. No offer, sale, resale, pledge, delivery, distribution or transfer of the Shares may be made except under circumstances that will not result in the Company being required to register as an investment company under the Investment Company Act. Neither the U.S. Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of the Shares or passed upon or endorsed the merits of the offering of the Shares or the adequacy or accuracy of the Prospectus. Any representation to the contrary is a criminal offence in the United States. In addition, the Shares are subject to restrictions on transferability and resale in certain jurisdictions and may not be transferred or resold except as permitted under applicable securities laws and regulations. Investors may be required to bear the financial risks of their investment in the Shares for an indefinite period of time. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdictions.

No liability whatsoever (whether in negligence or otherwise) arising directly or indirectly from the use of this document is accepted and no representation, warranty or undertaking, express or implied, is or will be made by the Company, or any of their respective directors, officers, employees, advisers, representatives or other agents ("Agents") for any information or any of the opinions contained herein or for any errors, omissions or misstatements. None of the Agents makes or has been authorised to make any representation or warranties (express or implied) in relation to the Company or as to the truth, accuracy or completeness of this document, or any other written or oral statement provided. In particular, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on any projections, targets, estimates or forecasts contained in this document and nothing in this document is or should be relied on as a promise or representation as to the future.

Unless otherwise indicated, the information provided herein is based on matters as they exist as of the date of preparation and not as of any future date. Recipients of this document are encouraged to contact the Company's representatives to discuss the procedures and methodologies used to make the projections and other information provided herein.

All investments are subject to risk, including the loss of the principal amount invested. Past performance is no guarantee of future returns. All investments to be held by the Company involve a substantial degree of risk, including the risk of total loss. The value of shares and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment you may get back less than you originally invested. You should always seek expert legal, financial, tax and other professional advice before making any investment decision.

The Company has been established in Jersey as a listed fund under a fast-track authorisation process. It is suitable therefore only for professional or experienced investors, or those who have taken appropriate professional advice. Further information in relation to the regulatory treatment of listed funds domiciled in Jersey may be found on the website of the Jersey Financial Services Commission at www.jerseyfsc.org. The Jersey Financial Services Commission does not take any responsibility for the financial soundness of the Company or for the correctness of any statements made or expressed in this document.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMGGMNFFGLZM
Date   Source Headline
22nd Apr 20247:00 amRNSDividend Declaration
22nd Apr 20247:00 amRNSNet Asset Value and Publication of Monthly Report
19th Apr 202412:31 pmRNSDirector Declaration
22nd Mar 20247:00 amRNSNet Asset Value and Publication of Monthly Report
23rd Feb 20244:44 pmRNSDIVIDEND CURRENCY ELECTION
22nd Feb 20247:00 amRNSNET ASSET VALUE AND PUBLICATION OF MONTHLY REPORT
23rd Jan 20247:00 amRNSDividend Declaration
22nd Jan 20245:05 pmRNSNet Asset Value and Publication of Monthly Report
22nd Dec 20237:00 amRNSCancellation of Treasury Shares
21st Dec 20234:13 pmRNSIssuance of Deferred Share
21st Dec 20237:00 amRNSNET ASSET VALUE AND PUBLICATION OF MONTHLY REPORT
21st Nov 20231:17 pmRNSDIVIDEND CURRENCY ELECTION
21st Nov 20237:00 amRNSNET ASSET VALUE AND PUBLICATION OF MONTHLY REPORT
13th Nov 20234:20 pmRNSQ3 2023 Report and Investor Call
20th Oct 20237:00 amRNSNet Asset Value(s)
20th Oct 20237:00 amRNSDividend Declaration
26th Sep 20237:00 amRNSHalf-year Report
21st Sep 20237:00 amRNSNET ASSET VALUE AND PUBLICATION OF MONTHLY REPORT
15th Sep 20231:21 pmRNSResult of Extraordinary General Meeting
25th Aug 20237:00 amRNSNotice of Extraordinary General Meeting
24th Aug 20234:07 pmRNSDirectorate Change
22nd Aug 20237:00 amRNSNet Asset Value and Publication of Monthly Report
9th Aug 20233:56 pmRNSQ2 2023 Report and Investor Call
26th Jul 20234:29 pmRNSBoard Update
26th Jul 20234:29 pmRNSResult of AGM
21st Jul 20237:00 amRNSDividend Declaration
21st Jul 20237:00 amRNSNet Asset Value and Publication of Monthly Report
10th Jul 20235:21 pmRNSNotice of Annual General Meeting
23rd Jun 20236:09 pmRNSProposed Managed Wind-Down of the Company
22nd Jun 20237:00 amRNSNET ASSET VALUE AND PUBLICATION OF MONTHLY REPORT
23rd May 20237:00 amRNSNet Asset Value and Publication of Monthly Report
11th May 20236:04 pmRNSQ1 2023 Report and Investor Call
28th Apr 20237:00 amRNSAnnual Financial Report
25th Apr 20237:00 amRNSDividend Declaration
25th Apr 20237:00 amRNSNet Asset Value(s)
3rd Apr 20234:54 pmRNSTotal Voting Rights
3rd Apr 20237:00 amRNSDirectorate Change
22nd Mar 20237:00 amRNSNet Asset Value(s)
17th Mar 20237:00 amRNSResults of Shareholder Consultation
2nd Mar 20235:31 pmRNSTransaction in Own Shares
2nd Mar 20235:08 pmRNSTransaction in Own Shares
1st Mar 20235:11 pmRNSTransaction in Own Shares
1st Mar 20233:05 pmRNSTotal Voting Rights
24th Feb 20234:18 pmRNSDIVIDEND CURRENCY ELECTION
22nd Feb 20237:00 amRNSNet Asset Value and Publication of Monthly Report
10th Feb 20234:48 pmRNSTransaction in Own Shares
10th Feb 20234:12 pmRNSNon-material change to Investment Policy
10th Feb 20231:58 pmRNSQ4 2022 Report and Investor Call
1st Feb 20233:36 pmRNSHolding(s) in Company
1st Feb 20231:10 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.